Federal Register #HHSOS20260332

HHS Solicits Public Input on Vaccine Recommendation Categories and Offers HPV T Cell Receptor License Opportunity

This opportunity from the U.S. Department of Health and Human Services (HHS), Office of the Secretary, seeks public input on federal vaccine recommendation categories and announces a license opportunity for novel T cell receptors targeting HPV. - Government Buyer: - U.S. Department of Health and Human Services (HHS) - Office of the Secretary - OEMs and Vendors: - No specific OEMs or commercial vendors are mentioned for the RFI - National Cancer Institute is offering a license for T cell receptors (as the developer) - Products/Services Requested: - Public comment on vaccine recommendation categories: routine, risk-based, and shared clinical decision-making - Input on potential new categories, communication strategies, and trust-building measures - License opportunity for T cell receptors targeting HPV 6 or HPV 11 (for treatment of recurrent respiratory papillomatosis and anogenital condyloma) - Unique/Notable Requirements: - Solicitation of public input to inform potential modifications to vaccine recommendation frameworks - Focus on scientific evidence, individual autonomy, legal/programmatic consequences, and communication practices - License opportunity addresses unmet needs in HPV-related diseases - No procurement of products or services is requested for the RFI; the license opportunity is for commercial development of a biomedical innovation.

Description

The Department of Health and Human Services (HHS), supporting the Task Force on Safer Childhood Vaccines, is seeking public comment on the adequacy of current categories used in Federal vaccine recommendations, which include routine (universal) recommendations, risk-based recommendations, and recommendations based on shared clinical decision-making. The Department is considering whether additional or different categories should be adopted and requests input on considerations such as scientific evidence strength, approaches when evidence is limited, individual autonomy, legal consequences, and communication practices to maintain public trust. Comments are invited to help inform potential modifications to vaccine recommendation frameworks and communication strategies.

View original listing